The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients

H. S. Eng, Z. Mohamed, R. Calne, C. C. Lang, M. A. Mohd, W. T. Seet, S. Y. Tan

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Cyclosporine is a substrate of cytochrome P-450 3A (CYP3A) subfamily of enzymes and characterized by a narrow therapeutic range with wide interindividual variation in pharmacokinetics. A few single-nucleotide polymorphisms detected in CYP3A genes have been shown to correlate significantly with the CYP3A protein expression and activity. We therefore postulated that these polymorphisms could be responsible for some of the interindividual variation in cyclosporine pharmacokinetics. The objective of our study is to determine correlation if any between single-nucleotide polymorphisms of CYP3A5 and CYP3AP1 on cyclosporine dose requirement and concentration-to-dose ratio in renal allograft recipients. Cyclosporine-dependent renal allograft recipients were genotyped for CYP3A5 A6986G and CYP3AP1 G-44A. The cyclosporine dosages prescribed and the corresponding cyclosporine trough levels for each patient were recorded so that cyclosporine dose per weight (mg/kg/day) and concentration-to-dose ratio (C0/D, whereby C0 is trough level and D is daily dose per weight) could be calculated. A total of 67 patients were recruited for our study. The dose requirement for 1, 3, and 6 months post-transplantation ranged 2.3-11.4, 1.0-9.0, and 1.4-7.2 mg/kg/day, respectively. Patients with *1*1*1*1 (n = 5) CYP3A5- and CYP3AP1-linked genotypes needed higher dose of cyclosporine compared to patients with *1*3*1*3 (n = 27) and *3* 3*3*3 (n = 33) linked genotypes in months 3 and 6 post-transplantation (P < 0.016). The identification of patients with *1*1* 1*1 by CYP3A5 and CYP3AP1 genotyping may have a clinically significant and positive impact on patient outcome with reduced rejection rate by providing pretransplant pharmacogenetic information for optimization of cyclosporine A dosing.

Original languageEnglish
Pages (from-to)1858-1864
Number of pages7
JournalKidney International
Volume69
Issue number10
DOIs
Publication statusPublished - May 2006
Externally publishedYes

Fingerprint

Cytochrome P-450 Enzyme System
Cyclosporine
Allografts
Kidney
Cytochrome P-450 CYP3A
Genes
Single Nucleotide Polymorphism
Pharmacokinetics
Transplantation
Genotype
Weights and Measures
Pharmacogenetics
Enzymes

Keywords

  • Cyclosporine
  • CYP3A
  • Gene polymorphism
  • Renal allograft

ASJC Scopus subject areas

  • Nephrology

Cite this

Eng, H. S., Mohamed, Z., Calne, R., Lang, C. C., Mohd, M. A., Seet, W. T., & Tan, S. Y. (2006). The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients. Kidney International, 69(10), 1858-1864. https://doi.org/10.1038/sj.ki.5000325

The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients. / Eng, H. S.; Mohamed, Z.; Calne, R.; Lang, C. C.; Mohd, M. A.; Seet, W. T.; Tan, S. Y.

In: Kidney International, Vol. 69, No. 10, 05.2006, p. 1858-1864.

Research output: Contribution to journalArticle

Eng, HS, Mohamed, Z, Calne, R, Lang, CC, Mohd, MA, Seet, WT & Tan, SY 2006, 'The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients', Kidney International, vol. 69, no. 10, pp. 1858-1864. https://doi.org/10.1038/sj.ki.5000325
Eng, H. S. ; Mohamed, Z. ; Calne, R. ; Lang, C. C. ; Mohd, M. A. ; Seet, W. T. ; Tan, S. Y. / The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients. In: Kidney International. 2006 ; Vol. 69, No. 10. pp. 1858-1864.
@article{8f0c514bed2f4532a79505c9e8eaef2d,
title = "The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients",
abstract = "Cyclosporine is a substrate of cytochrome P-450 3A (CYP3A) subfamily of enzymes and characterized by a narrow therapeutic range with wide interindividual variation in pharmacokinetics. A few single-nucleotide polymorphisms detected in CYP3A genes have been shown to correlate significantly with the CYP3A protein expression and activity. We therefore postulated that these polymorphisms could be responsible for some of the interindividual variation in cyclosporine pharmacokinetics. The objective of our study is to determine correlation if any between single-nucleotide polymorphisms of CYP3A5 and CYP3AP1 on cyclosporine dose requirement and concentration-to-dose ratio in renal allograft recipients. Cyclosporine-dependent renal allograft recipients were genotyped for CYP3A5 A6986G and CYP3AP1 G-44A. The cyclosporine dosages prescribed and the corresponding cyclosporine trough levels for each patient were recorded so that cyclosporine dose per weight (mg/kg/day) and concentration-to-dose ratio (C0/D, whereby C0 is trough level and D is daily dose per weight) could be calculated. A total of 67 patients were recruited for our study. The dose requirement for 1, 3, and 6 months post-transplantation ranged 2.3-11.4, 1.0-9.0, and 1.4-7.2 mg/kg/day, respectively. Patients with *1*1*1*1 (n = 5) CYP3A5- and CYP3AP1-linked genotypes needed higher dose of cyclosporine compared to patients with *1*3*1*3 (n = 27) and *3* 3*3*3 (n = 33) linked genotypes in months 3 and 6 post-transplantation (P < 0.016). The identification of patients with *1*1* 1*1 by CYP3A5 and CYP3AP1 genotyping may have a clinically significant and positive impact on patient outcome with reduced rejection rate by providing pretransplant pharmacogenetic information for optimization of cyclosporine A dosing.",
keywords = "Cyclosporine, CYP3A, Gene polymorphism, Renal allograft",
author = "Eng, {H. S.} and Z. Mohamed and R. Calne and Lang, {C. C.} and Mohd, {M. A.} and Seet, {W. T.} and Tan, {S. Y.}",
year = "2006",
month = "5",
doi = "10.1038/sj.ki.5000325",
language = "English",
volume = "69",
pages = "1858--1864",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients

AU - Eng, H. S.

AU - Mohamed, Z.

AU - Calne, R.

AU - Lang, C. C.

AU - Mohd, M. A.

AU - Seet, W. T.

AU - Tan, S. Y.

PY - 2006/5

Y1 - 2006/5

N2 - Cyclosporine is a substrate of cytochrome P-450 3A (CYP3A) subfamily of enzymes and characterized by a narrow therapeutic range with wide interindividual variation in pharmacokinetics. A few single-nucleotide polymorphisms detected in CYP3A genes have been shown to correlate significantly with the CYP3A protein expression and activity. We therefore postulated that these polymorphisms could be responsible for some of the interindividual variation in cyclosporine pharmacokinetics. The objective of our study is to determine correlation if any between single-nucleotide polymorphisms of CYP3A5 and CYP3AP1 on cyclosporine dose requirement and concentration-to-dose ratio in renal allograft recipients. Cyclosporine-dependent renal allograft recipients were genotyped for CYP3A5 A6986G and CYP3AP1 G-44A. The cyclosporine dosages prescribed and the corresponding cyclosporine trough levels for each patient were recorded so that cyclosporine dose per weight (mg/kg/day) and concentration-to-dose ratio (C0/D, whereby C0 is trough level and D is daily dose per weight) could be calculated. A total of 67 patients were recruited for our study. The dose requirement for 1, 3, and 6 months post-transplantation ranged 2.3-11.4, 1.0-9.0, and 1.4-7.2 mg/kg/day, respectively. Patients with *1*1*1*1 (n = 5) CYP3A5- and CYP3AP1-linked genotypes needed higher dose of cyclosporine compared to patients with *1*3*1*3 (n = 27) and *3* 3*3*3 (n = 33) linked genotypes in months 3 and 6 post-transplantation (P < 0.016). The identification of patients with *1*1* 1*1 by CYP3A5 and CYP3AP1 genotyping may have a clinically significant and positive impact on patient outcome with reduced rejection rate by providing pretransplant pharmacogenetic information for optimization of cyclosporine A dosing.

AB - Cyclosporine is a substrate of cytochrome P-450 3A (CYP3A) subfamily of enzymes and characterized by a narrow therapeutic range with wide interindividual variation in pharmacokinetics. A few single-nucleotide polymorphisms detected in CYP3A genes have been shown to correlate significantly with the CYP3A protein expression and activity. We therefore postulated that these polymorphisms could be responsible for some of the interindividual variation in cyclosporine pharmacokinetics. The objective of our study is to determine correlation if any between single-nucleotide polymorphisms of CYP3A5 and CYP3AP1 on cyclosporine dose requirement and concentration-to-dose ratio in renal allograft recipients. Cyclosporine-dependent renal allograft recipients were genotyped for CYP3A5 A6986G and CYP3AP1 G-44A. The cyclosporine dosages prescribed and the corresponding cyclosporine trough levels for each patient were recorded so that cyclosporine dose per weight (mg/kg/day) and concentration-to-dose ratio (C0/D, whereby C0 is trough level and D is daily dose per weight) could be calculated. A total of 67 patients were recruited for our study. The dose requirement for 1, 3, and 6 months post-transplantation ranged 2.3-11.4, 1.0-9.0, and 1.4-7.2 mg/kg/day, respectively. Patients with *1*1*1*1 (n = 5) CYP3A5- and CYP3AP1-linked genotypes needed higher dose of cyclosporine compared to patients with *1*3*1*3 (n = 27) and *3* 3*3*3 (n = 33) linked genotypes in months 3 and 6 post-transplantation (P < 0.016). The identification of patients with *1*1* 1*1 by CYP3A5 and CYP3AP1 genotyping may have a clinically significant and positive impact on patient outcome with reduced rejection rate by providing pretransplant pharmacogenetic information for optimization of cyclosporine A dosing.

KW - Cyclosporine

KW - CYP3A

KW - Gene polymorphism

KW - Renal allograft

UR - http://www.scopus.com/inward/record.url?scp=33646681672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646681672&partnerID=8YFLogxK

U2 - 10.1038/sj.ki.5000325

DO - 10.1038/sj.ki.5000325

M3 - Article

C2 - 16612333

AN - SCOPUS:33646681672

VL - 69

SP - 1858

EP - 1864

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 10

ER -